Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Biologic therapy.

Harvard Medical School, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, MA
Treatments:Chemotherapy, Biologic therapyHospital:Harvard Medical School
Drugs:Journal:Link
Date:Jan 2015

Description:

Patients:
This phase 2 study involved patients who were divided into groups based on their cancer type. Group A consisted of 24 glioblastoma patients with median age of 53 years; 41.7% were female. Group B had 15 anaplastic glioma patients with a median age of 48 years; 33.3% were female.

Treatment:
Patients in groups A and B received chemotherapy with panobinostat and biologic therapy with bevacizumab.

Toxicities:
The most severe toxicities in group A were of grade 4 and included brain hemorrhage and pulmonary embolism.

The most severe toxicities in group B were of grade 4 and included low blood phosphate levels and neutropenia.

Results:
The median overall survival for groups A and B was 9 and 17 months, respectively.

Support:
This study was supported by Novartis and Genentech.

Correspondence: Dr. Patrick Y.Wen; email: [email protected]



Back